Misplaced Pages

#923076

64-436: Antigens presented by MHC class II molecules are exogenous, originating from extracellular proteins rather than cytosolic and endogenous sources like those presented by MHC class I . The loading of a MHC class II molecule occurs by phagocytosis . Extracellular proteins are endocytosed into a phagosome , which subsequently fuses with a lysosome to create a phagolysosome . Within the phagolysosome, lysosomal enzymes degrade

128-455: A guanine exchange factor , loads ARL14/ARF7 with GTP. Subsequently, ARF7EP interacts with MYO1E which binds itself to actin myofibers. Altogether, this complex contributes to maintain MHC-II loaded vesicles within the immature dendritic cell , impeding its translocation to the cell membrane. One type of MHC class II deficiency, also called bare lymphocyte syndrome , is due to mutations in

192-438: A BCR binds a TD antigen, the antigen is taken up into the B cell through receptor-mediated endocytosis , degraded , and presented to T cells as peptide pieces in complex with MHC-II molecules on the cell membrane. T helper (T H ) cells , typically follicular T helper (T FH ) cells recognize and bind these MHC-II-peptide complexes through their T cell receptor (TCR) . Following TCR-MHC-II-peptide binding, T cells express

256-559: A common microbial constituent to toll-like receptors (TLRs) or by extensive crosslinking of BCRs to repeated epitopes on a bacterial cell. B cells activated by TI antigens go on to proliferate outside lymphoid follicles but still in SLOs (GCs do not form), possibly undergo immunoglobulin class switching, and differentiate into short-lived plasmablasts that produce early, weak antibodies mostly of class IgM, but also some populations of long-lived plasma cells. Memory B cell activation begins with

320-403: A different exon within the gene, and some genes have further domains that encode leader sequences, transmembrane sequences, etc. These molecules have both extracellular regions as well as a transmembrane sequence and a cytoplasmic tail. The α1 and β1 regions of the chains come together to make a membrane-distal peptide-binding domain, while the α2 and β2 regions, the remaining extracellular parts of

384-426: A full-force antibody immune response due to activation of B cells . During synthesis of class II MHC in the endoplasmic reticulum, the α and β chains are produced and complexed with a special polypeptide known as the invariant chain . The nascent MHC class II protein in the rough ER has its peptide-binding cleft blocked by the invariant chain (Ii; a trimer) to prevent it from binding cellular peptides or peptides from

448-443: A germinal center reaction where they generate plasma cells and more memory B cells. It is unclear whether the memory B cells undergo further affinity maturation within these secondary GCs. In vitro activation of memory B cells can be achieved through stimulation with various activators, such as pokeweed mitogen or anti- CD40 monoclonal antibodies , however, a study found a combination of R-848 and recombinant human IL-2 to be

512-409: A high predicted MHC binding affinity. Minor histocompatibility antigens, a conceptually similar antigen class are also correctly identified by MHC binding algorithms. Another potential filter examines whether the mutation is expected to improve MHC binding. The nature of the central TCR-exposed residues of MHC-bound peptides is associated with peptide immunogenicity. A native antigen is an antigen that

576-614: A host of cancers , including chronic lymphocytic leukemia (CLL) , acute lymphoblastic leukemia (ALL) , hairy cell leukemia , follicular lymphoma , non-Hodgkin's lymphoma , Hodgkin's lymphoma , and plasma cell malignancies such as multiple myeloma , Waldenström's macroglobulinemia , and certain forms of amyloidosis . Abnormal B cells may be relatively large and some diseases include this in their names, such as diffuse large B-cell lymphomas (DLBCLs) and intravascular large B-cell lymphoma . Patients with B cell alymphocytosis are predisposed to infections. A study that investigated

640-535: A lymphoid follicle and forming a germinal center (GC) , which is a specialized microenvironment where B cells undergo extensive proliferation, immunoglobulin class switching, and affinity maturation directed by somatic hypermutation. These processes are facilitated by T FH and follicular dendritic cells within the GC and generate both high-affinity memory B cells and long-lived plasma cells. Resultant plasma cells secrete large numbers of antibodies and either stay within

704-467: A multitude of different diseases, one of which being Type I diabetes . HLA class II genes are the most important genes associated with the risk of inheriting Type I diabetes, accounting for about 40-50% of heritability . Alleles of these genes that affect peptide binding to the MHC class II molecules seem to impact Type I diabetes risk the most. Specific allele polymorphisms have been identified to increase

SECTION 10

#1732786854924

768-572: A net equilibrium of phosphorylation and non-phosphorylation. It is only when the cell comes in contact with an antigen presenting cell that the larger CD45 is displaced due to the close distance between the two membranes. This allows for net phosphorylation of the BCR and the initiation of the signal transduction pathway . Of the three B cell subsets, FO B cells preferentially undergo T cell-dependent activation while MZ B cells and B1 B cells preferentially undergo T cell-independent activation. B cell activation

832-567: A state of central tolerance , in which the mature B cells do not bind self antigens present in the bone marrow. To complete development, immature B cells migrate from the bone marrow into the spleen as transitional B cells , passing through two transitional stages: T1 and T2. Throughout their migration to the spleen and after spleen entry, they are considered T1 B cells. Within the spleen, T1 B cells transition to T2 B cells. T2 B cells differentiate into either follicular (FO) B cells or marginal zone (MZ) B cells depending on signals received through

896-583: A two-step differentiation process that yields both short-lived plasmablasts for immediate protection and long-lived plasma cells and memory B cells for persistent protection. The first step, known as the extrafollicular response, occurs outside lymphoid follicles but still in the SLO. During this step activated B cells proliferate, may undergo immunoglobulin class switching, and differentiate into plasmablasts that produce early, weak antibodies mostly of class IgM. The second step consists of activated B cells entering

960-413: Is a deficiency in MHC class II molecules B cells are not activated and cannot differentiate into plasma cells which causes them to be deficient in antibodies which are unable to perform as they are expected. The only current form of treatment is a bone-marrow transplant however even this does not cure the disease and most patients do not live past age ten. MHC class II genes and molecules are related to

1024-432: Is also expressed on group 3 innate lymphoid cells . Having MHC class II molecules present proper peptides that are bound stably is essential for overall immune function. Because class II MHC is loaded with extracellular proteins, it is mainly concerned with presentation of extracellular pathogens (for example, bacteria that might be infecting a wound or the blood). Class II molecules interact mainly with immune cells, like

1088-465: Is called the antigen-antibody reaction . Antigen can originate either from within the body (" self-protein " or "self antigens") or from the external environment ("non-self"). The immune system identifies and attacks "non-self" external antigens. Antibodies usually do not react with self-antigens due to negative selection of T cells in the thymus and B cells in the bone marrow . The diseases in which antibodies react with self antigens and damage

1152-457: Is enhanced through the activity of CD21 , a surface receptor in complex with surface proteins CD19 and CD81 (all three are collectively known as the B cell coreceptor complex). When a BCR binds an antigen tagged with a fragment of the C3 complement protein, CD21 binds the C3 fragment, co-ligates with the bound BCR, and signals are transduced through CD19 and CD81 to lower the activation threshold of

1216-487: Is insufficient to exclude many false positives from the pool of peptides that may be presented by MHC molecules. Instead, algorithms are used to identify the most likely candidates. These algorithms consider factors such as the likelihood of proteasomal processing, transport into the endoplasmic reticulum , affinity for the relevant MHC class I alleles and gene expression or protein translation levels. The majority of human neoantigens identified in unbiased screens display

1280-403: Is not yet processed by an APC to smaller parts. T cells cannot bind native antigens, but require that they be processed by APCs, whereas B cells can be activated by native ones. Antigenic specificity is the ability of the host cells to recognize an antigen specifically as a unique molecular entity and distinguish it from another with exquisite precision. Antigen specificity is due primarily to

1344-525: Is then acquired and loaded onto a MHC II molecule. The MHC II molecule then travels to the surface to present the antigen to a helper T cell . MHC II activate helper T cells which help release cytokines and other things which will help induce other cells which help to combat the pathogens outside the cells. Several molecules are involved in this pathway. PIK3R2 and PIP5K1A are two kinases that phosphorylate Phosphatidylinositol (PIP) providing PSD4 with substrates for its GTP loading ability. PSD4 as

SECTION 20

#1732786854924

1408-516: Is usually a self-protein or protein complex (and sometimes DNA or RNA) that is recognized by the immune system of patients with a specific autoimmune disease . Under normal conditions, these self-proteins should not be the target of the immune system, but in autoimmune diseases, their associated T cells are not deleted and instead attack. Neoantigens are those that are entirely absent from the normal human genome. As compared with nonmutated self-proteins, neoantigens are of relevance to tumor control, as

1472-499: The T helper cell ( CD4 ). The peptide presented regulates how T cells respond to an infection. Stable peptide binding is essential to prevent detachment and degradation of a peptide, which could occur without secure attachment to the MHC molecule. This would prevent T cell recognition of the antigen, T cell recruitment, and a proper immune response. The triggered appropriate immune response may include localized inflammation and swelling due to recruitment of phagocytes or may lead to

1536-435: The bone marrow , which is at the core of most bones . In birds , B cells mature in the bursa of Fabricius , a lymphoid organ where they were first discovered by Chang and Glick, which is why the B stands for bursa and not bone marrow , as commonly believed. B cells, unlike the other two classes of lymphocytes, T cells and natural killer cells , express B cell receptors (BCRs) on their cell membrane . BCRs allow

1600-522: The plasma membrane by the APCs(antigen presenting cells). In some cells, antigens bind to recycled MHC class II molecules while they are in the early endosomes , while other cells such as dendritic cells internalize antigens via receptor-mediated endocytosis and create MHC class II molecules plus peptide in the endosomal-lysosomal antigen processing compartment which is independent of the synthesis of new MHC class II complexes. These suggest that after

1664-441: The B cell binds to an antigen via its BCR. Although the events taking place immediately after activation have yet to be completely determined, it is believed that B cells are activated in accordance with the kinetic segregation model , initially determined in T lymphocytes. This model denotes that before antigen stimulation, receptors diffuse through the membrane coming into contact with Lck and CD45 in equal frequency, rendering

1728-495: The B cell to bind to a foreign antigen , against which it will initiate an antibody response. B cell receptors are extremely specific, with all BCRs on a B cell recognizing the same epitope . B cells develop from hematopoietic stem cells (HSCs) that originate from bone marrow . HSCs first differentiate into multipotent progenitor (MPP) cells, then common lymphoid progenitor (CLP) cells. From here, their development into B cells occurs in several stages (shown in image to

1792-416: The BCR and other receptors. Once differentiated, they are now considered mature B cells, or naïve B cells. B cell activation occurs in the secondary lymphoid organs (SLOs), such as the spleen and lymph nodes . After B cells mature in the bone marrow, they migrate through the blood to SLOs, which receive a constant supply of antigen through circulating lymph . At the SLO, B cell activation begins when

1856-508: The HLA gene complex can lead to bare lymphocyte syndrome (BLS), which is a type of MHC class II deficiency. Like MHC class I molecules, class II molecules are also heterodimers , but in this case consist of two homogenous peptides, an α and β chain, both of which are encoded in the MHC. The subdesignation α1, α2, etc. refers to separate domains within the HLA gene; each domain is usually encoded by

1920-724: The SLO or, more preferentially, migrate to bone marrow. Antigens that activate B cells without T cell help are known as T cell-independent (TI) antigens and include foreign polysaccharides and unmethylated CpG DNA. They are named as such because they are able to induce a humoral response in organisms that lack T cells. B cell response to these antigens is rapid, though antibodies generated tend to have lower affinity and are less functionally versatile than those generated from T cell-dependent activation. As with TD antigens, B cells activated by TI antigens need additional signals to complete activation, but instead of receiving them from T cells, they are provided either by recognition and binding of

1984-579: The adjuvant component of vaccines plays an essential role in the activation of the innate immune system. An immunogen is an antigen substance (or adduct ) that is able to trigger a humoral (innate) or cell-mediated immune response. It first initiates an innate immune response, which then causes the activation of the adaptive immune response. An antigen binds the highly variable immunoreceptor products (B-cell receptor or T-cell receptor) once these have been generated. Immunogens are those antigens, termed immunogenic , capable of inducing an immune response. At

MHC class II - Misplaced Pages Continue

2048-414: The antigen is internalized, already existent MHC class II complexes on mature dendritic cells can be recycled and developed into new MHC class II molecules plus peptide. Unlike MHC I, MHC II is meant to present extracellular pathogens rather than intracellular. Furthermore, the first step is to acquire the pathogen through phagocytosis. The pathogen is then broken down in a lysosome and a desired component

2112-406: The antigens; depending on the antigen and the type of the histocompatibility molecule, different types of T cells will be activated. For T-cell receptor (TCR) recognition, the peptide must be processed into small fragments inside the cell and presented by a major histocompatibility complex (MHC). The antigen cannot elicit the immune response without the help of an immunologic adjuvant . Similarly,

2176-451: The body's own cells are called autoimmune diseases . Vaccines are examples of antigens in an immunogenic form, which are intentionally administered to a recipient to induce the memory function of the adaptive immune system towards antigens of the pathogen invading that recipient. The vaccine for seasonal influenza is a common example. Paul Ehrlich coined the term antibody ( German : Antikörper ) in his side-chain theory at

2240-469: The cell membrane. Memory T helper (T H ) cells, typically memory follicular T helper (T FH ) cells, that were derived from T cells activated with the same antigen recognize and bind these MHC-II-peptide complexes through their TCR. Following TCR-MHC-II-peptide binding and the relay of other signals from the memory T FH cell, the memory B cell is activated and differentiates either into plasmablasts and plasma cells via an extrafollicular response or enter

2304-460: The cell. Antigens that activate B cells with the help of T-cell are known as T cell-dependent (TD) antigens and include foreign proteins. They are named as such because they are unable to induce a humoral response in organisms that lack T cells. B cell responses to these antigens takes multiple days, though antibodies generated have a higher affinity and are more functionally versatile than those generated from T cell-independent activation. Once

2368-630: The chains, form a membrane-proximal immunoglobulin-like domain. The antigen binding groove, where the antigen or peptide binds, is made up of two α-helixes walls and β-sheet. Because the antigen-binding groove of MHC class II molecules is open at both ends while the corresponding groove on class I molecules is closed at each end, the antigens presented by MHC class II molecules are longer, generally between 15 and 24 amino acid residues long. These molecules are constitutively expressed in professional, immune antigen-presenting cells , but may also be induced on other cells by interferon γ . They are expressed on

2432-424: The destruction of the infected cell. Endogenous antigens are generated within normal cells as a result of normal cell metabolism , or because of viral or intracellular bacterial infection . The fragments are then presented on the cell surface in the complex with MHC class I molecules. If activated cytotoxic CD8 T cells recognize them, the T cells secrete various toxins that cause the lysis or apoptosis of

2496-420: The detection and binding of their target antigen, which is shared by their parent B cell. Some memory B cells can be activated without T cell help, such as certain virus-specific memory B cells, but others need T cell help. Upon antigen binding, the memory B cell takes up the antigen through receptor-mediated endocytosis, degrades it, and presents it to T cells as peptide pieces in complex with MHC-II molecules on

2560-428: The end of the 19th century. In 1899, Ladislas Deutsch (László Detre) named the hypothetical substances halfway between bacterial constituents and antibodies "antigenic or immunogenic substances" ( French : substances immunogènes ou antigènes ). He originally believed those substances to be precursors of antibodies, just as a zymogen is a precursor of an enzyme . But, by 1903, he understood that an antigen induces

2624-521: The endogenous pathway (such as those that would be loaded onto class I MHC). The invariant chain also facilitates the export of class II MHC from the ER to the Golgi apparatus , followed by fusion with a late endosome containing endocytosed, degraded proteins. The invariant chain is then broken down in stages by proteases called cathepsins , leaving only a small fragment known as CLIP which maintains blockage of

MHC class II - Misplaced Pages Continue

2688-605: The epithelial cells in the thymus and on APCs in the periphery. MHC class II expression is closely regulated in APCs by CIITA , which is the MHC class II transactivator. CIITA is solely expressed on professional APCs; however, non-professional APCs can also regulate CIITA activity and MHC II expression. As mentioned interferon γ (IFN γ) triggers the expression of CIITA and is also responsible for converting monocytes which are MHC class II negative cells into functional APCs that express MHC class II on their surfaces. MHC class II

2752-510: The fragments to T helper cells ( CD4 ) by the use of class II histocompatibility molecules on their surface. Some T cells are specific for the peptide:MHC complex. They become activated and start to secrete cytokines, substances that activate cytotoxic T lymphocytes (CTL), antibody-secreting B cells , macrophages and other particles. Some antigens start out as exogenous and later become endogenous (for example, intracellular viruses). Intracellular antigens can be returned to circulation upon

2816-458: The genes that code for transcription factors that regulate the expression of the MHC class II genes. It results in the depletion of CD4 T cells and some immunoglobulin isotypes even though there are normal levels of both CD8 Cells and B cells present. Deficient MHC class II molecules are unable to present antigens to T cells and properly activate T cells. T cells are then unable to proliferate, and secrete cytokines which normally participate in

2880-519: The immune response. Not only do the deficient MHC class II molecules affect the activation and proliferation of T cells but also the rest of the immune response cascade which includes B cells. Therefore, with this decrease in the number of T cells, the T cells cannot interact and activate the B cells. Normally when B cells are activated they divide, proliferate and differentiate, which includes the differentiation of these cells into plasma cells which are responsible for producing antibodies. However, when there

2944-482: The immune system so that each cell has a specificity for a single antigen. Upon exposure to an antigen, only the lymphocytes that recognize that antigen are activated and expanded, a process known as clonal selection . In most cases, antibodies are antigen-specific , meaning that an antibody can only react to and bind one specific antigen; in some instances, however, antibodies may cross-react to bind more than one antigen. The reaction between an antigen and an antibody

3008-435: The infected cell. In order to keep the cytotoxic cells from killing cells just for presenting self-proteins , the cytotoxic cells (self-reactive T cells) are deleted as a result of tolerance (negative selection). Endogenous antigens include xenogenic (heterologous), autologous and idiotypic or allogenic (homologous) antigens. Sometimes antigens are part of the host itself in an autoimmune disease . An autoantigen

3072-699: The molecular level, an antigen can be characterized by its ability to bind to an antibody's paratopes . Different antibodies have the potential to discriminate among specific epitopes present on the antigen surface. A hapten is a small molecule that can only induce an immune response when attached to a larger carrier molecule, such as a protein . Antigens can be proteins, polysaccharides, lipids , nucleic acids or other biomolecules. This includes parts (coats, capsules, cell walls, flagella, fimbriae, and toxins) of bacteria , viruses , and other microorganisms . Non-microbial non-self antigens can include pollen, egg white, and proteins from transplanted tissues and organs or on

3136-456: The most efficient activator. Autoimmune disease can result from abnormal B cell recognition of self-antigens followed by the production of autoantibodies. Autoimmune diseases where disease activity is correlated with B cell activity include scleroderma , multiple sclerosis , systemic lupus erythematosus , type 1 diabetes , post-infectious IBS , and rheumatoid arthritis . Malignant transformation of B cells and their precursors can cause

3200-401: The peptide binding cleft on the MHC molecule. A MHC class II-like structure, HLA-DM , facilitates CLIP removal and allows the binding of peptides with higher affinities. The stable class II MHC is then presented on the cell surface. After MHC class II complexes are synthesized and presented on APCs they are unable to be expressed on the cell surface indefinitely, due to the internalization of

3264-422: The plasma membrane where they serve as a part of B-cell receptors . When a naïve or memory B cell is activated by an antigen, it proliferates and differentiates into an antibody-secreting effector cell, known as a plasmablast or plasma cell. In addition, B cells present antigens (they are also classified as professional antigen-presenting cells, APCs ) and secrete cytokines . In mammals B cells mature in

SECTION 50

#1732786854924

3328-539: The pool of neoantigens. Tumor antigens are those antigens that are presented by MHC class I or MHC class II molecules on the surface of tumor cells . Antigens found only on such cells are called tumor-specific antigens (TSAs) and generally result from a tumor-specific mutation . More common are antigens that are presented by tumor cells and normal cells, called tumor-associated antigens (TAAs). Cytotoxic T lymphocytes that recognize these antigens may be able to destroy tumor cells. Tumor antigens can appear on

3392-464: The pre-BCR and the BCR. If these receptors do not bind to their ligand , B cells do not receive the proper signals and cease to develop. Negative selection occurs through the binding of self-antigen with the BCR; if the BCR can bind strongly to self-antigen, then the B cell undergoes one of four fates: clonal deletion , receptor editing , anergy , or ignorance (B cell ignores signal and continues development). This negative selection process leads to

3456-465: The production of immune bodies (antibodies) and wrote that the word antigen is a contraction of antisomatogen ( Immunkörperbildner ). The Oxford English Dictionary indicates that the logical construction should be "anti(body)-gen". The term originally referred to a substance that acts as an antibody generator. Antigen-presenting cells present antigens in the form of peptides on histocompatibility molecules . The T cells selectively recognize

3520-476: The protein-coding part of the genome (the exome ) and predict potential neoantigens. In mice models, for all novel protein sequences, potential MHC-binding peptides were predicted. The resulting set of potential neoantigens was used to assess T cell reactivity. Exome–based analyses were exploited in a clinical setting, to assess reactivity in patients treated by either tumor-infiltrating lymphocyte (TIL) cell therapy or checkpoint blockade. Neoantigen identification

3584-546: The proteins into peptide fragments . These fragments are then loaded into the peptide-binding groove of the MHC class II molecule. Once loaded, the MHC class II-peptide complexes are transported to the plasma membrane via vesicular transport , where they present the antigens to the extracellular environment. In humans, the MHC class II protein complex is encoded by the human leukocyte antigen gene complex (HLA) . HLAs corresponding to MHC class II are HLA-DP , HLA-DM , HLA-DOA , HLA-DOB , HLA-DQ , and HLA-DR . Mutations in

3648-436: The quality of the T cell pool that is available for these antigens is not affected by central T cell tolerance. Technology to systematically analyze T cell reactivity against neoantigens became available only recently. Neoantigens can be directly detected and quantified. For virus-associated tumors, such as cervical cancer and a subset of head and neck cancers , epitopes derived from viral open reading frames contribute to

3712-462: The right), each marked by various gene expression patterns and immunoglobulin H chain and L chain gene loci arrangements, the latter due to B cells undergoing V(D)J recombination as they develop. B cells undergo two types of selection while developing in the bone marrow to ensure proper development, both involving B cell receptors (BCR) on the surface of the cell. Positive selection occurs through antigen-independent signalling involving both

3776-761: The risk (such as DRB1 and DQB1). Others have been associated with a resistance to the disease. Antigens In immunology , an antigen ( Ag ) is a molecule , moiety , foreign particulate matter , or an allergen , such as pollen , that can bind to a specific antibody or T-cell receptor . The presence of antigens in the body may trigger an immune response . Antigens can be proteins , peptides (amino acid chains), polysaccharides (chains of simple sugars), lipids , or nucleic acids . Antigens exist on normal cells , cancer cells , parasites , viruses , fungi , and bacteria . Antigens are recognized by antigen receptors, including antibodies and T-cell receptors. Diverse antigen receptors are made by cells of

3840-494: The side-chain conformations of the antigen. It is measurable and need not be linear or of a rate-limited step or equation. Both T cells and B cells are cellular components of adaptive immunity . B cell B cells , also known as B lymphocytes , are a type of white blood cell of the lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system . B cells produce antibody molecules which may be either secreted or inserted into

3904-454: The surface of the tumor in the form of, for example, a mutated receptor, in which case they are recognized by B cells . For human tumors without a viral etiology, novel peptides (neo-epitopes) are created by tumor-specific DNA alterations. A large fraction of human tumor mutations are effectively patient-specific. Therefore, neoantigens may also be based on individual tumor genomes. Deep-sequencing technologies can identify mutations within

SECTION 60

#1732786854924

3968-460: The surface of transfused blood cells. Antigens can be classified according to their source. Exogenous antigens are antigens that have entered the body from the outside, for example, by inhalation , ingestion or injection . The immune system's response to exogenous antigens is often subclinical. By endocytosis or phagocytosis , exogenous antigens are taken into the antigen-presenting cells (APCs) and processed into fragments. APCs then present

4032-704: The surface protein CD40L as well as cytokines such as IL-4 and IL-21 . CD40L serves as a necessary co-stimulatory factor for B cell activation by binding the B cell surface receptor CD40 , which promotes B cell proliferation , immunoglobulin class switching , and somatic hypermutation as well as sustains T cell growth and differentiation. T cell-derived cytokines bound by B cell cytokine receptors also promote B cell proliferation, immunoglobulin class switching, and somatic hypermutation as well as guide differentiation. After B cells receive these signals, they are considered activated. Once activated, B cells participate in

4096-404: Was successful for multiple experimental model systems and human malignancies. The false-negative rate of cancer exome sequencing is low—i.e.: the majority of neoantigens occur within exonic sequence with sufficient coverage. However, the vast majority of mutations within expressed genes do not produce neoantigens that are recognized by autologous T cells. As of 2015 mass spectrometry resolution

#923076